Prosecution Insights
Last updated: November 04, 2026
Application No. 17/925,916

Notch Inhibitors and Uses Thereof

Non-Final OA §102§112
Filed
Nov 17, 2022
Priority
May 21, 2020 — provisional 63/028,188 +1 more
Examiner
JARRELL, NOBLE E
Art Unit
1699
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Stemsynergy Therapeutics Inc.
OA Round
3 (Non-Final)
81%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
91%
With Interview

Examiner Intelligence

Grants 81% — above average
81%
Career Allowance Rate
857 granted / 1058 resolved
+21.0% vs TC avg
Moderate +10% lift
Without
With
+9.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
61 currently pending
Career history
1109
Total Applications
across all art units

Statute-Specific Performance

§101
2.5%
-37.5% vs TC avg
§103
17.0%
-23.0% vs TC avg
§102
20.5%
-19.5% vs TC avg
§112
44.4%
+4.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1058 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 2026 August 4 containing claims 2-3, 7, 10-12, 16, 19, 22, 26, 30-31, 35, 37, 39-40, 42-43, 46-47, 50, 52, 55, 57, 61, 79 and 82-83 has been entered. The 35 U.S.C. 102 rejection of 2026 May 22 is overcome because ring A is no longer pyridyl. A search of formula (I) is extended to compounds in which L2 is selected from a bond, -N(RL2)-, -0-, -5-, -SO2-, -C(O)-, -C(O)N(RL2)-, -N(RL2)C(O)-, -N(RL2)C(O)NH-,-NHC(O)N(RL2)-, -C(O)O-, -OC(O)-, -SO2N(RL2)-, -N(RL2)SO2-, substituted or unsubstituted alkylene, or -O-(CH2)2-. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claim(s) 2-3, 7, 10-12, 16, 19, 22, 26, 30-31, 35, 37, 39-40, 42-43, 46-47, 50, 52, 55, 57, 61, 79 and 82-83 is/are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph due to lack of written description. The MPEP states that the purpose of the written description requirement is to ensure that the inventor had possession, as of the filing date of the application, of the specific subject matter later claimed by him. The MPEP lists factors that can be used to determine if sufficient evidence of possession has been furnished in the disclosure of the Application. These include “level of skill and knowledge in the art, partial structure, physical and/or chemical properties, functional characteristics alone or coupled with a known or disclosed correlation between structure and function, and the method of making the claimed invention. Disclosure of any combination of such identifying characteristics that distinguish the claimed invention from other materials and would lead one of skill in the art to the conclusion that the applicant was in possession of the claimed species is sufficient.” MPEP § 2163. While all of the factors have been considered, a sufficient amount for a prima facie case are discussed below. In the instant case, claims 2-3, 7, 10-12, 16, 19, 22, 26, 30-31, 35, 37, 39-40, 42-43, 46-47, 50, 52, 55, 57, 61, 79 and 82-83 are drawn to a compound of formula (I) in which examined variable A is phenyl. Examined variable L2 represents a bond or numerous linking groups, connecting rings B and C. The limitation “unsubstituted or substituted heteroalkylene” lacks written description because applicants do not have possession of all of the embodiments of this linking group (specification, pages 6-7, paragraphs [0032]-[0033]). Examined variable L2 is critical to this formula because it is always present. PNG media_image1.png 228 146 media_image1.png Greyscale (1) Level of skill and knowledge in the art: NINKOVIC (WO 2010/016005, published 2010 February 11) describes heterolkylene groups can be the following shown below (page 46, lines 24-29). PNG media_image2.png 154 602 media_image2.png Greyscale (2) Physical and/or chemical properties and (4) Functional characteristics: The 1H-NMR and liquid chromatography mass spectrometric properties of the prepared compounds of the examined application were analyzed (page 267, paragraph [0594] to page 352, paragraph [0912]). The compounds of the examined application are Notch-1 inhibitors (specification, page 354, paragraph [0914] to page 357, paragraph [0918]). (4) Method of making the claimed invention: Synthetic preparation of compounds in which L2 is -O-CH2- are described analyzed (page 267, paragraph [0594] to page 352, paragraph [0912]). The MPEP states that written description for a genus can be achieved by a representative number of species within a broad generic. It is unquestionable that claim(s) 2-3, 7, 10-12, 16, 19, 22, 26, 30-31, 35, 37, 39-40, 42-43, 46-47, 50, 52, 55, 57, 61, 79 and 82-83 is/are broad and generic, with respect to all possible compounds encompassed by the claims. The possible structural variations are limitless to any non-cyclic heteroalkylene group that contains at least one carbon and one heteroatom. Although the claims may recite some functional characteristics, the claims lack written description because there is no disclosure of a correlation between function and structure of the compounds beyond those compounds specifically disclosed in the examples in the specification. Moreover, the specification lack sufficient variety of species to reflect this variance in the genus. While having written description of instances of examined variable L2 as -CH2-CH2-S-CH2-CH2-, -CH2-S-CH2-CH2-NH-CH2-, and -O-CH2-, and compounds identified in the specification tables and/or examples, the specification does not provide sufficient descriptive support for the myriad of compounds embraced by the claims. The description requirement of the patent statue requires a description of an invention, not an indication of a result that one might achieve if one made that invention. See In re Wilder, 736, F.2d 1516, 1521, 222 USPQ 369, 372-73 (Fed. Cir. 1984) (affirming rejection because the specification does “little more than outlin[e] goals appellants hope the claimed invention achieves and the problems the invention will hopefully ameliorate.”) Accordingly, it is deemed that the specification fails to provide adequate written description for the genus of the claims and does not reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the entire scope of the claimed invention. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 11, 12, and 16 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 11, 12, and 16 recites the limitation that one of variables R4A or R4B is an unsubstituted alkoxy group. There is insufficient antecedent basis for this limitation in the claim because nor of the groups for these variables recites an unsubstituted alkoxy group. Each alkoxy group is substituted with Cl, F, Br, or I. PNG media_image3.png 150 548 media_image3.png Greyscale Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 2 and 26 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by BEATTY (WO 2020/046813, published 2020 March 5). Beatty describes two intermediate compounds, the starting material and final products of step d of example 29 (page 68, line 18 to page 70, line 24). In these two compounds, the following examined definitions apply: L1-R1 is -CH2-O-(CH2)2-SiMe3 [heteroalkylene substituted with a substituted alkyl group]; R2 is -CH2-O-(CH2)2-SiMe3, a substituted alkyl group; ring B is a pyridopyrazole ring, unsubstituted or substituted with a methyl group; L2 is a direct bond; ring C is pyrazole substituted with a p-cyano-benzyl group [a substituted alkyl group]. PNG media_image4.png 382 302 media_image4.png Greyscale Improper Markush Rejection Claims 2-3, 7, 10-12, 16, 19, 22, 26, 30-31, 35, 37, 39-40, 42-43, 46-47, 50, 52, 55, 57, 61, 79 and 82-83 are rejected on the basis that it contains an improper Markush grouping of alternatives. See In re Harnisch, 631 F.2d 716, 721-22 (CCPA 1980) and Ex parte Hozumi, 3 USPQ2d 1059, 1060 (Bd. Pat. App. & Int. 1984). A Markush grouping is proper if the alternatives defined by the Markush group (i.e., alternatives from which a selection is to be made in the context of a combination or process, or alternative chemical compounds as a whole) share a “single structural similarity” and a common use. A Markush grouping meets these requirements in two situations. First, a Markush grouping is proper if the alternatives are all members of the same recognized physical or chemical class or the same art-recognized class, and are disclosed in the specification or known in the art to be functionally equivalent and have a common use. Second, where a Markush grouping describes alternative chemical compounds, whether by words or chemical formulas, and the alternatives do not belong to a recognized class as set forth above, the members of the Markush grouping may be considered to share a “single structural similarity” and common use where the alternatives share both a substantial structural feature and a common use that flows from the substantial structural feature. See MPEP § 2117. The Markush grouping of a heteroalkylene group for variable L2 is improper because the alternatives defined by the Markush grouping do not share both a single structural similarity and a common use for the following reasons: The definition of this group (specification, pages 6-7, paragraphs [0032]-[0033]) shows a heteroalklyene chain is a non-cyclic group with any number of carbons and heteroatoms together. The two groups exemplified below show this idea. These groups are different lengths, contain different numbers of carbons, and different combinations of heteroatoms. In claim 60, the heteroalkylene linker is -O-CH2-. Based on the variance of the exemplified groups encompassed by this term, a single structural similarity is not present. PNG media_image5.png 24 486 media_image5.png Greyscale To overcome this rejection, Applicant may set forth each alternative (or grouping of patentably indistinct alternatives) within an improper Markush grouping in a series of independent or dependent claims and/or present convincing arguments that the group members recited in the alternative within a single claim in fact share a single structural similarity as well as a common use. Conclusion Claims 2-3, 7, 10-12, 16, 19, 22, 26, 30-31, 35, 37, 39-40, 42-43, 46-47, 50, 52, 55, 57, 61, 79 and 82-83 are not allowed. Claim 60 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. The following is a statement of reasons for the indication of allowable subject matter: BEATTY (WO 2020/046813, published 2020 March 5) does not describe compounds in which ring B is phenylene. Any inquiry concerning this communication or earlier communications from the examiner should be directed to NOBLE E JARRELL whose telephone number is (571)272-9077. The examiner can normally be reached 8:00 AM to 4:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Fereydoun Sajjadi can be reached at 571-272-3311. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /NOBLE E JARRELL/Primary Examiner, Art Unit 1699
Read full office action

Prosecution Timeline

Nov 17, 2022
Application Filed
Oct 30, 2025
Non-Final Rejection mailed — §102, §112
Jan 22, 2026
Response Filed
May 22, 2026
Final Rejection mailed — §102, §112
Jul 08, 2026
Response after Non-Final Action
Aug 04, 2026
Request for Continued Examination
Aug 14, 2026
Response after Non-Final Action
Oct 02, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780815
Process for the Production of Ferroportin Inhibitors
4y 1m to grant Granted Nov 03, 2026
Patent 12778122
ANTIBACTERIAL COMPOSITION
3y 7m to grant Granted Nov 03, 2026
Patent 12780785
AZABICYCLO[3.1.0]HEXANE COMPOUND
2y 10m to grant Granted Nov 03, 2026
Patent 12767669
GALLIUM-SALOPHEN ANTIMICROBIAL COMPOUNDS AND METHODS OF USE THEREOF
3y 10m to grant Granted Oct 20, 2026
Patent 12767657
MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF
3y 7m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
81%
Grant Probability
91%
With Interview (+9.9%)
2y 11m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1058 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month